Quoin Pharmaceuticals (NASDAQ:QNRX) Posts Earnings Results, Misses Estimates By $6.39 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) released its earnings results on Tuesday. The company reported ($6.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($6.39), Zacks reports.

Quoin Pharmaceuticals Stock Up 3.9%

QNRX opened at $6.36 on Wednesday. The business has a 50 day moving average of $7.87 and a 200-day moving average of $15.17. The stock has a market cap of $3.74 million, a PE ratio of -1.57 and a beta of 1.39. Quoin Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $54.95.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.